Dr. Patricia A. Locantore-Ford
Claim this profilePennsylvania Hospital
Studies Cancer
Studies Lymphoma
6 reported clinical trials
22 drugs studied
Area of expertise
1Cancer
Stage IV
CD4+ cell count positive
CD4+ cell count negative
2Lymphoma
Stage IV
CD4+ cell count positive
CD4+ cell count negative
Affiliated Hospitals
Clinical Trials Patricia A. Locantore-Ford is currently running
Nivolumab + Ipilimumab
for Cancer
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory), or solid tumors that have spread from where it first started to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ipilimumab is an antibody that acts against a molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 controls a part of the immune system by shutting it down. Nivolumab is a type of antibody that is specific for human programmed cell death 1 (PD-1), a protein that is responsible for destruction of immune cells. Giving ipilimumab with nivolumab may work better in treating patients with HIV associated classical Hodgkin lymphoma or solid tumors compared to ipilimumab with nivolumab alone.
Recruiting1 award Phase 127 criteria
Pomalidomide
for Kaposi Sarcoma
This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
Recruiting1 award Phase 221 criteria
More about Patricia A. Locantore-Ford
Clinical Trial Related8 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Patricia A. Locantore-Ford has experience with
- Nivolumab
- Ipilimumab
- Ibrutinib
- Rituximab
- Cyclophosphamide
- Doxorubicin Hydrochloride
Breakdown of trials Patricia A. Locantore-Ford has run
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Patricia A. Locantore-Ford specialize in?
Patricia A. Locantore-Ford focuses on Cancer and Lymphoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are CD4+ cell count positive.
Is Patricia A. Locantore-Ford currently recruiting for clinical trials?
Yes, Patricia A. Locantore-Ford is currently recruiting for 6 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Patricia A. Locantore-Ford has studied deeply?
Yes, Patricia A. Locantore-Ford has studied treatments such as Nivolumab, Ipilimumab, Ibrutinib.
What is the best way to schedule an appointment with Patricia A. Locantore-Ford?
Apply for one of the trials that Patricia A. Locantore-Ford is conducting.
What is the office address of Patricia A. Locantore-Ford?
The office of Patricia A. Locantore-Ford is located at: Pennsylvania Hospital, Philadelphia, Pennsylvania 19107 United States. This is the address for their practice at the Pennsylvania Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.